Cocrystal Pharma Inc. | Mutual Funds
Mutual Funds that own Cocrystal Pharma Inc.
1,012,025
3.38%
104,695
3.86%
06/30/2018
iShares Micro Cap ETF
31,162
0.1%
0
0.01%
09/06/2018
Vanguard Balanced Index Fund
20,600
0.07%
0
0%
07/31/2018
Vanguard Total Stock Market Index Fund
11,638
0.04%
11,638
0%
07/31/2018
Vanguard Extended Market Index Fund
3,604
0.01%
3,604
0%
07/31/2018
| Address |
19805 North Creek Parkway
Bothell Washington 98011
United States
|
|
Employees
|
- |
| Website |
http://www.cocrystalpharma.com |
| Updated |
07/08/2019 |
| Cocrystal Pharma, Inc. is a clinical stage biotechnology company, which engages in discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of Hepatitis C. Phase 1b studies in Hepatitis C infected patients showed the largest reduction in viral load of any non-neoside inhibitor tested to date. |
